

## Adverse Drug Reaction (ADR) reporting form (Initial and follow up)

Enter dates in format DD/MM/YYYY throughout the form

Case ID:				Date of receipt of information:				
☐ Initial report				Follow up information requested				
☐ Follow up report			☐ Yes	☐ Yes				
			☐ No					
1. Patient Information	1	Data available	□ No	☐ Yes (please	complete the section below)			
Initials	Gender:	□F□M	Age:		Estimated date			
	Weight:	kg	Age		of delivery:			
		1,9	Group:					
	Height:	cm	Date of Birth:					
	Pregnancy:	□ No □ Yes	Trimester:	☐ 1st ☐ 2nd ☐ 3rd				
		cy, please fill the p	regnancy re					
Any additional relevar					ital discharge summary, la-			
boratory values, conco	mitant condition	ons or concomitant m	nedication)					
2-Information on the	e adverse dru	g reaction :						
ADR 1*		ADR 2		ADR3	ADR 4			
Date :		Date:	Da	 te :	Date :			
			•					
ADR (s) Description:								
	Start Date: (DD /MM /YYYY)							
<u>Dates</u>								
	Stop Date: (DD /MM /YYYY)							
	□ Ongoing							
	☐ Ongoing ☐ Recovering							
	☐ Recovering							
<u>Outcome</u>	☐ Recovered without Sequelae ☐ Recovered with Sequelae (specify):							
	☐ Fatal/Death							
	□ Unknown							
	□ Non-serious							
<u>Seriousness</u>	☐ Serious (If serious, please complete following):							
	□ Serious (ii serious, piease complete ioliowing):							

MEMPHIS PHARMACEUTICALS & CHEMICAL INDUSTRIES

<mark>مهفیس للأدویت والصناعات الکیماویت</mark> ۱ مشارع السواح - الأمیریة - ۱۹۲۸ - الثاهرة - مصر تنفراهیار( ممخیس ) مص ۱ مشارع السواح - الأمیریة ۲۲۰ (۲ ۲۰۲۰ (۲ ۲۰۲۰) ۲۰۰ ۱ مشارک - ۲۰۰ (۲ ۲۰۲۰) ۲۲۸۲۲۷ (۲ ۲۰۰ ۱ مسارک - ۲۰۰ (۲ ۲۰۲۰) سemphis ⊕holdipharma.com پریت الکترونی Marmphis ⊕mamphis conneg



## Memphis Pharm. & Chemical Ind شركه ممفيس للادويه والصناعات الكيماويه

		]	<ul> <li>□ Death Date: Autopsy □ No □ Yes (please provide copy of autopsy report)</li> <li>□ Life-threatening</li> <li>□ Hospitalization (&gt; 24 h)</li> <li>□ Prolongation of existing hospitalization (&gt; 24 h)</li> <li>□ Persistent or significant disability/incapacity</li> <li>□ Congenital anomaly/Birth defect</li> <li>□ Medically important (e.g., patient requires intervention to prevent one of outcomes listed above)</li> </ul>								
Cau	Causal Relationship  Causal Relationship  Causal Relationship  □ Probable/ Likely (reasonable time relationship; unlikely to be attributed to other plausible cause) □ Possible (reasonable time relationship; could be attributed to other plausible cause) □ Unlikely □ Not related □ Un-assessable (To be used for, e.g. Pregnancy, medication errors etc.,)										
			No No								
			☐ Yes (specify medication administered for treatment):								
Corrective therapy (treatment required		N	ame of product	Daily Dose	Route/Form	Start Date: (DD /MM /YYYY)		Stop Date : (DD /MM /YYYY)			
to t	reat the reported										
ADR?)		N	ame of product	Daily Dose	Route/Form			top Date: D /MM /YYYY)			
2 5	uspect products										
3-3	Product name	•	Active ingredien	t Dosage	Route of administration	on Start date	End date	Indication			
1											
2											
3											
Action taken with suspected products?		-	- Withdrawn due to Adverse drug reaction (ADR):  □ No □ Yes (specify): □ Resolution of suspected ADR □ Improvement of suspected ADR □ No improvement of suspected ADR - Reintroduced □ No □ Yes (specify): □ Recurrence of suspected ADR □ Dosage reduced due to ADR?								
	☐ Indicate the new dose										



## Memphis Pharm. & Chemical Ind شركه ممفيس للادويه والصناعات الكيماويه

4-Reporter details								
<ul><li>□ Physician</li><li>□ Patient/consumer/family member</li><li>□ Other, specify:</li></ul>	Name	Address	Country	Phone/ Fax/ Email				
Is the report associated with a product technical complaint (PTC)								
□ Yes								
□ No								
Comments:								

## **Privacy Notification:**

The information in this report is confidential and totally protected including both the patient and the reporter.

Please provide all available information and send completed form to Memphis Company:

E-mail: PV@memphis.com.eg

Tel.no: 202/22829880

**Attach any applicable supporting documentation if applicable** (such as pictures, autopsy report, hospital discharge summary, laboratory values).

<sup>\*</sup>Reporting for ADRs is vital for safety usage of the drug. Enough information will help to evaluate the safety of the drug.